Contract Pharma

Breaking News | Drug Development | Industry News

Bristol Myers Squibb Expands at Cambridge Crossing

Adds remaining 113,000 square feet to its initial lease at 250 Water Street.

Kristin Brooks 04.16.21

Breaking News | Drug Development | Industry News

Amgen Completes Five Prime Acquisition

Gains pipeline of immuno-oncology and targeted cancer therapies, including a Phase 3 trial-ready, first-in-class program for gastric cancer.

Kristin Brooks 04.16.21

Breaking News | Drug Development | Industry News

BioVersys Gets EIB Funds to Address Antimicrobial Resistance

Financing supports development of BioVersys’ breakthrough hospital antibiotic therapy targeting Acinetobacter baumannii

Kristin Brooks 04.14.21

APIs | Drug Development | Process Validation

Exploring ICP-MS expertise at Almac

A discussion about Inductively Coupled Plasma Mass Spectrometry (ICP-MS) and its importance within drug development.

Breaking News | Clinical Trials | Drug Development | Trials & Filings

FDA Accepts Airway Therapeutics’ IND for COVID Treatment

To initiate a Phase 1b trial to confirm the feasibility of intratracheal administrations of AT-100 and its beneficial safety and tolerability profile.

Kristin Brooks 04.12.21

Biologics, Proteins, Vaccines | Breaking News | Drug Development | Industry News

Sanofi Acquires Tidal Therapeutics

Gains novel mRNA-based technology with research capabilities in immuno-oncology and inflammatory diseases, with potential in other disease areas.

Kristin Brooks 04.12.21

Analytical Services | Breaking News | Clinical Trial Materials | Drug Development | Industry News

Ascendia Pharmaceuticals Poised for Expansion

CDMO secures growth equity investment from Signet Healthcare Partners.

Tim Wright, Editor, Contract Pharma 04.09.21

Breaking News | Collaborations & Alliances | Drug Delivery | Drug Development | Industry News

Kindeva Drug Delivery and Cambridge Healthcare Innovations Collaborate

Work together to develop and commercialize CHI’s novel dry-powder inhaler product.

Charles Sternberg, Assistant Editor 04.07.21

Breaking News | Clinical Trials | Drug Development | Industry News

Sound Pharmaceuticals Receives $3.1M NIH Grant for COVID Treatment

To support the testing of SPI-1005 in two Phase 2 clinical trials for the treatment of COVID-19.

Kristin Brooks 04.06.21

Breaking News | Clinical Trials | CRO News | Drug Development

Moleculin Selects IQVIA Biotech to Advance COVID Treatment

IQVIA to manage the company's effort to begin potential clinical trials of WP1122 for the treatment of COVID-19.

Kristin Brooks 04.06.21

Clinical Trials | Drug Development | QA/QC

RBQM Comes of Age: COVID as a Catalyst for Change

Clinical trial conduct has undergone a fundamental shift over the last year – and things will never be the same again.

Online Exclusives Kristin Brooks, Managing Editor 04.01.21

Breaking News | Drug Development

Servier Acquires Agios Pharmaceuticals’ Oncology Portfolio

Expands its oncology leadership capabilities in the U.S.

Charles Sternberg, Assistant Editor 04.01.21

Biologics, Proteins, Vaccines | Breaking News | Drug Development | Industry News

Eloxx Pharmaceuticals Acquires Zikani Therapeutics

Combined company brings complementary Ribosomal RNA-targeted genetic therapy platforms together.

Kristin Brooks 04.01.21

Clinical Trial Materials | Drug Development | Formulation Development

On-Demand Webinar: Accelerated Timelines for Clinical Supply Manufacture

Watch this on-demand webinar to gain a deeper understanding of the value of adaptive processes at this critical early stage of drug development.

Biologics, Proteins, Vaccines | Breaking News | Drug Development | Industry News

Ajinomoto, Bright Peak Enter Immunocytokines Research Pact

Exclusive license agreement to incorporate Ajinomoto Co.’s AJICAP site-specific bioconjugation technology for the development of Bright Peak Immunocytokines.

Kristin Brooks 03.30.21

Chime Biologics Expands CDMO Capabilities

Completes $190 million financing round to accelerate capacity expansion.

Tim Wright, Editor, Contract Pharma 03.29.21

cGMP Manufacture | Drug Development | Scale-up/Technology Transfer

Fast Track Automation in Pharmaceutical Manufacturing

Drug manufacturers turn to advanced automation technologies and project execution methodologies to reduce time, cost and risk

Steve Zarichniak, Technical Solutions Consultant, Honeywell Process Solutions 03.25.21

CyanVac and Exothera Enter COVID-19 Vaccine Partnership

CDMO Exothera selected for the development and GMP manufacturing of intranasal vaccine candidate for Phase III clinical trial is Europe and the U.S.

Tim Wright, Editor, Contract Pharma 03.25.21

Drug Development

Accelerate Your Program: Streamlined Phase Appropriate Technologies & Expertise

In this webinar on April 21, learn how the technologies of the OneXpress™ Solution can help streamline development and manufacturing and more.

03.25.21

Breaking News | Drug Development | Facilities | Industry News | Parenterals

Eisai Begins Construction of New Injection/Research Building

To accommodate expanded drug discovery targets and new modalities such as antibodies, ADCs, and nucleic acid drugs.

Kristin Brooks 03.22.21

Biologics, Proteins, Vaccines | Breaking News | Collaborations & Alliances | Drug Development | Drug Discovery

Evotec, Takeda Enter Multi-RNA Target Alliance

To discover and develop small molecule therapeutics for highly attractive targets that are difficult to address via more conventional approaches.

Kristin Brooks 03.22.21

Clinical Trials | Drug Development

Regulatory Practices in a Post-Pandemic World

Envisioning the new normal for clinical development.

Dr. Ronan Brown, SVP and Head of Integrated Global Compliance, IQVIA 03.22.21

Breaking News | Clinical Trials | Drug Development | Trials & Filings

Gilead, Novo Nordisk Expand NASH Alliance

Phase II trial to investigate Novo’s semaglutide and a combination of Gilead’s cilofexor and firsocostat, alone and in combination in cirrhosis due to NASH.

Kristin Brooks 03.18.21

Breaking News | Clinical Trials | Drug Development | Trials & Filings

Cytocom Gets FDA Clearance for Phase II Trial of COVID Immune Therapy

Phase 2 clinical trial to evaluate the safety and efficacy of CYTO-205 as a treatment to slow or halt the progression of SARS-CoV-2.

Kristin Brooks 03.16.21

Biologics, Proteins, Vaccines | Breaking News | Drug Development | Industry News

Selexis, Pandion Enter Antibody Service Agreement

Pandion will leverage Selexis’ SUREtechnology Platform to advance an antibody targeting autoimmune and inflammatory diseases.

Kristin Brooks 03.16.21

PhaseBio and BioVectra Enter into Supply Agreement

To support development and commercialization of bentracimab.

Tim Wright 03.11.21

Breaking News | Collaborations & Alliances | Drug Development

Selexis SA and BITT Enter Service Agreement

Will develop the cell line for BITR2101, BITT’s lead tumor necrosis factor receptor 2 oncology candidate.

Charles Sternberg, Assistant Editor 03.10.21

Breaking News | cGMP Manufacture | Drug Development | Industry News

Vetter Establishes Office in China

Additional office in Asia Pacific region to promote development of new business in China.

Kristin Brooks 03.08.21

Innoforce and dMed Enter Development Collaboration

Aims to accelerate the development of innovative therapeutics.

Tim Wright, Editor, Contract Pharma 03.03.21

Breaking News | Collaborations & Alliances | Drug Development | Industry News | Solid Dosage/Creams/Ointments

Pfizer Partners with Medicines Manufacturing Innovation Center

To transform the formulation of oral solid dosage medicines.

Tim Wright, Editor, Contract Pharma 02.25.21

Breaking News | Drug Development | Industry News

Cyprium, Sentynl Therapeutics Ink Asset Purchase Agreement

Sentynl acquires CUTX-101 Copper Histidinate for the treatment of Menkes disease for $20 million in upfront and regulatory milestones.

Kristin Brooks 02.24.21

Biologics, Proteins, Vaccines | Breaking News | Drug Development | Industry News | Information Technology

Pfizer Selects Seven Bridges to Support RNA Sequencing Data

Seven Bridges will centralize and manage terabytes scRNASeq data, which provides detailed analysis of gene expression in individual cells.

Kristin Brooks 02.24.21

Breaking News | Drug Development | Promotions & Moves

Aevitas Therapeutics Appoints President and CEO

Dr. Markus Peters offers a 25-year track record of developing and commercializing orphan and specialty pharmaceuticals.

Charles Sternberg, Assistant Editor 02.22.21

Drug Development

Embedding Your Drug Strategy Within a Solid Foundation for Success

This whitepaper looks at the broad set of trends inﬂuencing pharmaceutical development and manufacturing strategy today.

Breaking News | Collaborations & Alliances | Drug Development

Lilly, Rigel Enter Exclusive CNS Development Collaboration

Lilly will pay $125 million upfront and up to $835 million in potential milestones for Rigel's lead RIPK1 inhibitor, R552.

Kristin Brooks 02.18.21

Biologics, Proteins, Vaccines | Breaking News | Collaborations & Alliances | Drug Development

Biomunex, Onward Ink Strategic Antibody Development Pact

Exclusive worldwide license and development agreement will leverage Biomunex' next gen bi- and multi-specific antibody platform in hematological malignancies.

Kristin Brooks 02.16.21

Lonza Expands Solid Small Molecule Services

To encompass all aspects of solid form screening and characterization of small molecule APIs.

Kristin Brooks 02.16.21

Biologics, Proteins, Vaccines | Collaborations & Alliances | Drug Development

Molecular Templates, BMS Enter Strategic Research Pact

Aims to discover and develop multiple therapies for specific oncology targets utilizing MTEM’s next-gen engineered toxin body (ETB) platform.

Kristin Brooks 02.11.21

AbbVie, Caribou Ink CAR-T Collaboration

Leverages Caribou's next-generation CRISPR genome editing technology platform and AbbVie's antigen-specific binders.

Tim Wright, Editor, Contract Pharma 02.10.21

Breaking News | Drug Development | Industry News | Laboratory Testing

Quotient Sciences Acquires Arcinova

Acquisition expands Quotient’s services with drug substance, drug product and clinical testing capabilities.

Kristin Brooks 02.09.21

Bio News | Biologics, Proteins, Vaccines | Breaking News | Drug Development | Industry News

Paragon Biosciences Expands Cell and Gene Therapy Platform

Launches CiRC Biosciences with an initial focus on developing eye disease treatments.

Tim Wright, Editor, Contract Pharma 02.08.21

Biologics, Proteins, Vaccines | Breaking News | Drug Development | Trials & Filings

J&J Submits EUA for Single-Shot Janssen COVID Vax Candidate

Plans to distribute vaccine to U.S. government immediately following authorization, and expects to supply 100 million doses in 1H21.

Kristin Brooks 02.05.21

Biologics, Proteins, Vaccines | cGMP Manufacture | Drug Development

The Future of Vaccines and Biologics

Dr. Linda Marbán of Capricor Therapeutics discusses the advances in responding to infectious diseases.

Online Exclusives Kristin Brooks, Managing Editor, Contract Pharma 02.04.21

Biologics, Proteins, Vaccines | Breaking News | Drug Development | Trials & Filings

Vaxart Oral COVID-19 Vax Tablet Shows Promise

Phase I study reached primary and secondary endpoints of safety and immunogenicity.

Kristin Brooks 02.03.21

Breaking News | Clinical Trials | Drug Development | Industry News

Affimed, Roche Explore AFM24, Tecentriq Combo

To investigate the combination for the treatment of advanced solid epidermal growth factor receptor (EGFR) expressing malignancies.

Kristin Brooks 02.03.21

Breaking News | Collaborations & Alliances | Drug Development

Imcyse, Pfizer Enter Autoimmune Research Alliance

Will develop Imotope candidates to potentially treat Rheumatoid Arthritis.

Charles Sternberg, Assistant Editor 02.03.21

Immunome, Abzena Enter COVID-19 Antibody Cocktail Agreement

Abzena will work with Immunome to produce the antibody cocktail for clinical testing.

Kristin Brooks 02.03.21

cGMP Manufacture | Drug Development | Process Development | R&D

Importance of Green Chemistry in Drug Development And Manufacturing

Learn how one CDMO is at the forefront of green chemistry, applying its principles to reduce the environmental and human impact of pharmaceutical production.